secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMGC Holdings Inc. (ELAB)
CIK:        0001840563
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001213900-26-048252
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMGC subsidiary NorthStrive files U.S. patent for EL-22 muscle preservation in humans
--------------------------------------------------------------------------------

- New U.S. patent application (No. 19/655,160) covers EL-22 as a formulated pharmaceutical product for muscle loss.
- EL-22 uses myostatin-engineered probiotic technology targeting sarcopenia, disuse atrophy, and neurological disorders.
- The patent includes dosing regimens and formulations; potential use with GLP-1 receptor agonist weight loss treatments.
- This filing expands NorthStrive's IP strategy for muscle health therapeutics across pharmaceutical and adjacent markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026048252/0001213900-26-048252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026048252/ea0287845-8k_pmgc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-048252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer